... efficacy for limited-disease small cell lung cancer (LD-SCLC) are lacking. The inflammation-based Glasgow Prognostic Score (GPS), comprising serum C-reactive protein (CRP) and albumin levels, can predict survival in advanced cancer. This study investigated whether metabolic and inflammatory markers...

... concentrations. Few studies have assessed the correlation between the GPS and the efficacy of chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC). Therefore, this study aimed to evaluate the utility of the GPS in predicting the survival outcomes of patients with ES-SCLC. Methods...

...Venu Madhav Konala; Bhaskar Reddy Madhira; Sara Ashraf; Stephen Graziano Lung cancer is a leading cause of cancer death in the United States and around the world. Approximately 13% of lung cancers are small cell lung cancer (SCLC). SCLC is generally classified as a limited-stage and extensive-stage...

...Eun Joo Kang; Suk Young Lee; Hong Jun Kim; Kyung Hoon Min; Gyu Young Hur; Jae Jeong Shim; Kyung Ho Kang; Sang Cheul Oh; Jae Hong Seo; Sung Yong Lee; Jun Suk Kim Background/Objective: The aim of this study was to evaluate the characteristics and prognostic factors of small cell lung cancer (SCLC...

...Yu-Hsuan Kuo; Zhong-Zhe Lin; Yen-Yun Yang; Yu-Yun Shao; Wen-Yi Shau; Raymond N.C. Kuo; James Chih-Hsin Yang; Mei-Shu Lai Background: Small cell lung cancer (SCLC) is the most aggressive form of lung cancer. The prognosis for SCLC patients remains unsatisfactory despite advances in chemotherapy...

...Soojung Hong; Byoung Chul Cho; Hye Jin Choi; Minkyu Jung; Soo Hyeon Lee; Kyung Soo Park; Se Kyu Kim; Joo Hang Kim Objective: The aims of this study were to identify prognostic factors for overall survival (OS) in patients with small cell lung cancer (SCLC) and to construct a prognostic index...

... human (rh)TPO and recombinant human stem cell factor (rhSCF) on eight small cell lung cancer (SCLC) cell lines and one leukemic cell line, CMK, with megakaryocyte characteristics. rhTPO did not reveal any stimulatory effects on all eight SCLC cell lines, while rhSCF demonstrated a modest growth...

...A.L. Jones; J. Holborn; S. Ashley; I.E. Smith In an attempt to achieve adequate palliation in patients with small cell lung cancer (SCLC) while keeping toxicity to a minimum, we compared CVM (car-boplatin/vinblastine/methotrexate) and standard therapy with ACE (doxoru-bicin/cyclophosphamide...

...M. de Wet; G. Falkson; B.L. Rapoport The aims of this study were to identify prognostic factors in patients (pts) with small cell lung cancer and to identify dominant prognostic factors independent of disease stage, to define prognostic subsets through recursive partitioning and amalgamation (RPA...

...Kiyoyuki Furuse; Kaoru Kubota; Masaaki Kawahara; Minoru Takada; Ikuro Kimura; Masafumi Fujii; Mitsuo Ohta; Kouichi Hasegawa; Kiyokazu Yoshida; Shigenori Nakajima; Takeshi Ogura; Hisanohu Niitani Twenty-four previously treated patients with refractory or relapsed small cell lung cancer (SCLC) were...

...Noriyuki Masuda; Masahiro Fukuoka; Kiyoyuki Furuse CODE therapy demonstrated high antitumor activity in extensive-stage small cell lung cancer (SCLC). Toxicity was acceptable in a regimen with a nine-cycle schedule. The results obtained in this study suggest that CODE therapy improves the outcome...

...Anthony Greco; Patrick B. Murphy; John D. Hainsworth; Kenneth R. Hande; David H. Johnson Etoposide is a highly schedule-dependent agent. We previously reported that a 21-day schedule of oral etoposide had good activity in small cell lung cancer (SCLC). The current phase II study was designed...

...Ulrich Gatzemeier; Joachim von Pawel; Reiner Laumen; Dieter K. Hossfeld; Renate Neuhauss; Martin Reck; Luigi Lenaz Carboplatin is one of the most active agents in untreated small cell lung cancer (SCLC; 14% complete response, CR; and 61% CR + partial response, PR). The combination carboplatin...

...Nobuyuki Hara; Yukito Ichinose; Tomoharu Kuda; Hiroshi Asoh; Tokujiro Yano; Masayuki Kawasaki; Mitsuo Ohta Long-term survival (≥3 years) was evaluated in 164 patients with small cell lung cancer (SCLC). Thirty-seven patients underwent surgical resection, and 127 did not. All but one resected...

... as in oat cell-type SCCL. This preliminary study suggests that 201 Tl/ 67 Ga uptake ratio is a possible prognostic indicator of SCCL. 201 Tl/ 67 Ga uptake ratio Small cell lung cancer Neuron-specific enolase © 1987 S. Karger AG, Basel 1987 Copyright / Drug Dosage / Disclaimer Copyright: All...

...M. Marangolo; P. Giovanis Recent literature about the treatment options of small cell lung cancer stresses the role of ifosfamide both alone and in combination with either cisplatin or carboplatin and etoposide. Its pharmacokinetics and the lower hematological toxicity permit the use of high doses...

...Joan H. Schiller Small cell lung cancer (SCLC) is characterized by early dissemination and a rapid, aggressive clinical course. It has, however, marked susceptibility to both chemotherapy and radiotherapy, although treatment is complicated by the fact that SCLC tumors invariably develop resistance...

...Yoshinobu Ohsaki; Andrew J. Gross; Phuong Tram Le; Herbert Oie; BruceE. Johnson The tumoral production of brain natriuretic peptide (BNP) was studied using 9 small cell lung cancer (SCLC) cell lines which were established from patients with small cell lung cancer. BNP cDNA fragment was generated...